Extended Data Fig. 9: Crunch therapy in an SLE mice model.
From: Phagocytic clearance of targeted cells with a synthetic ligand
a, Strategy for Crunch therapy in MRLlpr/lpr SLE mice. MRLlpr/lpr mice were treated with saline, 150 µg scGFP-Crunch (scGFP), or scCD19–Crunch (scCD19) twice per week from 8 to 13 weeks of age. After therapy, spleen, blood, and kidneys were collected for B cell and renal analysis. MRL mice without treatment served as controls. b-d, Crunch therapy effects. The number of splenocytes (b), body weight (c), and spleen weight normalized by body weight (d) were assessed (MRL n = 1, Saline n = 7, scGFP n = 3, scCD19 n = 9 mice). e-f, Renal histology. Histopathologic scores of glomerular lesions were graded on a scale from 0-3 (e), based on H&E staining in Fig. 6k (Saline n = 7, scGFP n = 3, scCD19 n = 9 mice). IgG deposition levels in glomerular lesions were measured by Alexa647 MFI (f), as shown in Fig. 6l (Saline n = 4, scGFP, n = 3, scCD19 n = 6 mice). Saline (e P = 0.00000081, f P = 0.0019), scGFP (e P = 0.00025, f P = 0.0041), compared with scCD19. Data are mean ± S.D. Statistical analyses were performed using one-way ANOVA with Tukey-Kramer t test. Significance is indicated by N.S. P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001.
